Alnylam EVP Tanguler sells $632k in stock

Tolga Tanguler, Executive Vice President and Chief Commercial Officer at Alnylam Pharmaceuticals , INC. (NASDAQ:ALNY), which has seen its stock surge 83% over the past six months and currently trades near its 52-week high of $462.88, sold a total of 1396 shares of common stock on August 18, 2025. The sales were executed at prices ranging from $447.98 to $455.82, resulting in a total transaction value of $632758.

The transactions follow the acquisition of 2851 shares of Alnylam Pharmaceuticals, INC. common stock on August 15, 2025, at a price of $0.00.

Following these transactions, Tanguler directly owns 29466 shares of Alnylam Pharmaceuticals, INC.

In other recent news, Alnylam Pharmaceuticals reported second-quarter earnings that significantly exceeded analyst expectations. The company posted adjusted earnings of $0.32 per share, surpassing the consensus estimate of -$0.59. Revenue for the quarter reached $773.7 million, well above the projected $643.2 million, with total net product revenues increasing 64% year-over-year to $672.2 million, primarily driven by strong sales of AMVUTTRA for ATTR cardiomyopathy. Oppenheimer upgraded Alnylam Pharmaceuticals from Perform to Outperform, setting a price target of $490.00, highlighting the stronger-than-expected sales of Amvuttra, which generated approximately $150 million in its first full quarter, far exceeding both Oppenheimer’s and consensus estimates. Wolfe Research also upgraded Alnylam Pharmaceuticals from Underperform to Peerperform, citing improved patient acquisition capabilities. Truist Securities reiterated its Buy rating on the company, maintaining a price target of $459.00, as anticipation builds for the upcoming presentation of zilebesiran KARDIA3 data at the European Society of Cardiology conference. These developments reflect positive momentum for Alnylam Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.